A comparison of two risk prediction tools used to calculate an individual’s risk of developing cardiovascular disease (CVD) suggests that the long-term, 30-year risk should be considered in addition to the short-term, 10-year risk to help inform when to begin medication therapy for stage 1 hypertension, or high blood pressure, according to new research published today in Hypertension, an American Heart Association journal.
Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug